Cargando…
THU380 A Case Of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient With Type 2 Diabetes Mellitus And Rechallenge With SGLT2 Inhibitor
Disclosure: V. Sekar: None. S. Shaik: None. Introduction: Alpelisib is a α-selective phosphatidylinositol 3-kinase (PI3K) inhibitor recently used in treatment of advanced breast cancer. Hyperglycemia is an expected adverse effect with the use of PI3K inhibitors. We report a case of Alpelisib induced...
Autores principales: | Sekar, Vijaykumar, Shaik, Shamsuddin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555321/ http://dx.doi.org/10.1210/jendso/bvad114.813 |
Ejemplares similares
-
THU259 Alpelisib-induced Diabetic Ketoacidosis: Call For A Multidisciplinary Approach
por: Kalara, Niketa, et al.
Publicado: (2023) -
THU360 Hyperglycemic DKA In Patient On Monotherapy With SGLT-2 Inhibitor
por: Ahmed, Samihah, et al.
Publicado: (2023) -
THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023) -
Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021) -
THU247 Characterizing Inpatient Cases Of DKA Precipitated By SGLT2 Inhibitor Use
por: Aslamy, Arianne, et al.
Publicado: (2023)